Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 415

1.

Loss of heterozygosity, aberrant methylation, BRAF mutation and KRAS mutation in colorectal signet ring cell carcinoma.

Kakar S, Deng G, Smyrk TC, Cun L, Sahai V, Kim YS.

Mod Pathol. 2012 Jul;25(7):1040-7. doi: 10.1038/modpathol.2012.44. Epub 2012 Apr 20.

2.

BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features.

Pai RK, Jayachandran P, Koong AC, Chang DT, Kwok S, Ma L, Arber DA, Balise RR, Tubbs RR, Shadrach B, Pai RK.

Am J Surg Pathol. 2012 May;36(5):744-52. doi: 10.1097/PAS.0b013e31824430d7.

PMID:
22314188
3.

Distinct molecular features of colorectal carcinoma with signet ring cell component and colorectal carcinoma with mucinous component.

Ogino S, Brahmandam M, Cantor M, Namgyal C, Kawasaki T, Kirkner G, Meyerhardt JA, Loda M, Fuchs CS.

Mod Pathol. 2006 Jan;19(1):59-68.

4.

Clinicopathologic and molecular features of sporadic early-onset colorectal adenocarcinoma: an adenocarcinoma with frequent signet ring cell differentiation, rectal and sigmoid involvement, and adverse morphologic features.

Chang DT, Pai RK, Rybicki LA, Dimaio MA, Limaye M, Jayachandran P, Koong AC, Kunz PA, Fisher GA, Ford JM, Welton M, Shelton A, Ma L, Arber DA, Pai RK.

Mod Pathol. 2012 Aug;25(8):1128-39. doi: 10.1038/modpathol.2012.61. Epub 2012 Apr 6.

5.

Prognostic significance and molecular features of signet-ring cell and mucinous components in colorectal carcinoma.

Inamura K, Yamauchi M, Nishihara R, Kim SA, Mima K, Sukawa Y, Li T, Yasunari M, Zhang X, Wu K, Meyerhardt JA, Fuchs CS, Harris CC, Qian ZR, Ogino S.

Ann Surg Oncol. 2015 Apr;22(4):1226-1235. doi: 10.1245/s10434-014-4159-7. Epub 2014 Oct 18.

6.

Associations between colorectal cancer molecular markers and pathways with clinicopathologic features in older women.

Samadder NJ, Vierkant RA, Tillmans LS, Wang AH, Weisenberger DJ, Laird PW, Lynch CF, Anderson KE, French AJ, Haile RW, Potter JD, Slager SL, Smyrk TC, Thibodeau SN, Cerhan JR, Limburg PJ.

Gastroenterology. 2013 Aug;145(2):348-56.e1-2. doi: 10.1053/j.gastro.2013.05.001. Epub 2013 May 7.

7.

Colorectal carcinomas with KRAS mutation are associated with distinctive morphological and molecular features.

Rosty C, Young JP, Walsh MD, Clendenning M, Walters RJ, Pearson S, Pavluk E, Nagler B, Pakenas D, Jass JR, Jenkins MA, Win AK, Southey MC, Parry S, Hopper JL, Giles GG, Williamson E, English DR, Buchanan DD.

Mod Pathol. 2013 Jun;26(6):825-34. doi: 10.1038/modpathol.2012.240. Epub 2013 Jan 25.

8.

Clinicopathologic characteristics, CpG island methylator phenotype, and BRAF mutations in microsatellite-stable colorectal cancers without chromosomal instability.

Kakar S, Deng G, Sahai V, Matsuzaki K, Tanaka H, Miura S, Kim YS.

Arch Pathol Lab Med. 2008 Jun;132(6):958-64. doi: 10.1043/1543-2165(2008)132[958:CCCIMP]2.0.CO;2.

PMID:
18517279
9.
10.

CpG island methylator phenotype-positive tumors in the absence of MLH1 methylation constitute a distinct subset of duodenal adenocarcinomas and are associated with poor prognosis.

Fu T, Pappou EP, Guzzetta AA, Jeschke J, Kwak R, Dave P, Hooker CM, Morgan R, Baylin SB, Iacobuzio-Donahue CA, Wolfgang CL, Ahuja N.

Clin Cancer Res. 2012 Sep 1;18(17):4743-52. doi: 10.1158/1078-0432.CCR-12-0707. Epub 2012 Jul 23.

11.

Possible role of Cdx2 in the serrated pathway of colorectal cancer characterized by BRAF mutation, high-level CpG Island methylator phenotype and mismatch repair-deficiency.

Dawson H, Galván JA, Helbling M, Muller DE, Karamitopoulou E, Koelzer VH, Economou M, Hammer C, Lugli A, Zlobec I.

Int J Cancer. 2014 May 15;134(10):2342-51. doi: 10.1002/ijc.28564. Epub 2013 Nov 13.

12.

Frequent mutations of KRAS in addition to BRAF in colorectal serrated adenocarcinoma.

Stefanius K, Ylitalo L, Tuomisto A, Kuivila R, Kantola T, Sirniö P, Karttunen TJ, Mäkinen MJ.

Histopathology. 2011 Apr;58(5):679-92. doi: 10.1111/j.1365-2559.2011.03821.x. Epub 2011 Apr 4.

13.
14.

CpG island methylator phenotype in colorectal cancers: comparison of the new and classic CpG island methylator phenotype marker panels.

Lee S, Cho NY, Yoo EJ, Kim JH, Kang GH.

Arch Pathol Lab Med. 2008 Oct;132(10):1657-65. doi: 10.1043/1543-2165(2008)132[1657:CIMPIC]2.0.CO;2.

PMID:
18834226
15.

Prognostic significance and molecular associations of 18q loss of heterozygosity: a cohort study of microsatellite stable colorectal cancers.

Ogino S, Nosho K, Irahara N, Shima K, Baba Y, Kirkner GJ, Meyerhardt JA, Fuchs CS.

J Clin Oncol. 2009 Sep 20;27(27):4591-8. doi: 10.1200/JCO.2009.22.8858. Epub 2009 Aug 24.

16.
17.

Involvement of the serrated neoplasia pathway in inflammatory bowel disease-related colorectal oncogenesis.

Bossard C, Denis MG, Bézieau S, Bach-Ngohou K, Bourreille A, Laboisse CL, Mosnier JF.

Oncol Rep. 2007 Nov;18(5):1093-7.

PMID:
17914558
18.

Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation.

Lee S, Cho NY, Choi M, Yoo EJ, Kim JH, Kang GH.

Pathol Int. 2008 Feb;58(2):104-13. doi: 10.1111/j.1440-1827.2007.02197.x.

PMID:
18199160
19.

Association between molecular subtypes of colorectal cancer and patient survival.

Phipps AI, Limburg PJ, Baron JA, Burnett-Hartman AN, Weisenberger DJ, Laird PW, Sinicrope FA, Rosty C, Buchanan DD, Potter JD, Newcomb PA.

Gastroenterology. 2015 Jan;148(1):77-87.e2. doi: 10.1053/j.gastro.2014.09.038. Epub 2014 Sep 30.

20.

Mutations in both KRAS and BRAF may contribute to the methylator phenotype in colon cancer.

Nagasaka T, Koi M, Kloor M, Gebert J, Vilkin A, Nishida N, Shin SK, Sasamoto H, Tanaka N, Matsubara N, Boland CR, Goel A.

Gastroenterology. 2008 Jun;134(7):1950-60, 1960.e1. doi: 10.1053/j.gastro.2008.02.094. Epub 2008 Mar 8.

Supplemental Content

Support Center